🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

No clear benefit to adding docetaxel to long term ADT for high-risk or very high-risk #prostatecancer patients getting #radiation. Can use #abiraterone for the highest risk groups, but still an unmet need of how to improve outcomes for these patients. #ASCO2025

REASSURE – Long-term safety of Ra-223 in mCRPC: 7-yr F/U UroToday.com #ASCO25 Bayer Oncology Medical 🔷n=1,472; med F/U 17 mo (range: 0.3-95.4) 🔷2nd primary malig: n=25 (2%), MC lung, skin ca 🔷Fracture rate: 10% 🔷MC 2nd agent: Doce (18%), Enza (15%) 🔷mOS: 15.6 mo

Important real world data that even if PSA drops 90% in mHSPC - that is not good enough unless PSA is <0.2. Let’s set the bar correctly! <0.2 is the goal - anything less is not good enough. ADT + ARPI much more likely to get PSA <0.2. #ASCO25

Highlighting this The PCCTC and DCI Center for Prostate & Urologic Cancers trial of a novel CTLA engaging IO plus Lu177-PSA-617 therapy in men with mCRPC at #ASCO25 #MedIQASCO25 with Tian Zhang, MD, MHS . Clear activity and safe!

EXTEND showed us that MDT + ADT > ADT RADIOSA showed MDT + ADT > MDT. STORM / PEACE-V showed ENI + MDT + ADT > MDT + ADT All studies had some novel imaging defined mHSPC (STORM was 100% novel) Can we just accept that MDT (+/- elective RT) + ADT is better than either?!?

Choi shares key differences in tumor genetic profiles from Black & non-Hispanic Whites pts in Caris database. Black pts had higher SPOP & CDK12 mutations & HRRd alterations. Suggests Black men w mCRPC have greater response to ENZA or PARP inhibitors (for HRRd) than whites

CAN-2409 is the first oncolytic and immunogenicity virus to delay progression in intermediate risk prostate cancer! Great work from Johns Hopkins University Ted DeWeese at #ASCO25 #MedIQASCO25. N=744 HR for DFS 0.52 p=.0155

Phase 3 of novel viral vector in #prostatecancer pts getting XRT. Intermediate to high-risk. Despite slide title - only helps w/o ADT but not w/ADT. Curves separate at 24 mos when biopsies done. Unlikely to help high risk w/ADT but may replace ADT for intermediate risk? #ASCO25

Digital pathology and clinical multimodal AI again can predict treatment needs in prostate cancer, now with abiraterone in STAMPEDE at #ASCO25 #MedIQASCO25 ArteraAI in very high risk disease! Predictive and prognostic for MFS, PCSM.

Nice analysis from IRONMAN matching our VA results presented yesterday: in mHSPC - if the PSA is not <0.2 that is bad. Let’s set the bar correctly- the goal is PSA <0.2. PSA <0.1 does even better! #ASCO25

Updated results from #ARCHES in mHSPC showing sustained benefits of #enzalutamide with minimum 5 year followup. 3 year survival benefit in high volume disease! Amazing results! Andrew Armstrong Arun Azad #ASCO25

Primary results from phase 3 #AMPLITUDE trial showing significant benefits to adding #niraparib, a #PARPi, to mHSPC patients with HRR mutations. Great to have new options to treat #prostatecancer pts who have HRR mutations which portends a poor prognosis. #ASCO25

Thank you! #MedIQASCO25 and #ASCO25 for their support and Pfizer Inc. and Astellas Pharma US and DCI Center for Prostate & Urologic Cancers for so much support in these meaningful results!

Darolutamide is now U.S. FDA approved for mHSPC based on ARANOTE study results #ASCO25 #mHSPC #ProstateCancer OncoAlert high5md ESMO - Eur. Oncology European Association of Urology (EAU) fda.gov/drugs/resource…

🎬 Watch World GU chairs Drs. Alicia Morgans, MD, MPH and Dan George reveal what to expect at #WorldGU25. Join them in Nashville, TN from Aug 21-23 at this 2-day CE-accredited conference. Register today: hubs.la/Q03qSqF00 #guoncology #cme

Optimizing multidisciplinary care for metastatic hormone-sensitive #ProstateCancer. Zach Klaassen Georgia Cancer Center joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss optimizing #mHSPC care through treatment intensification + multidisciplinary teamwork. Despite proven benefits, many still

Honored to give a keynote lecture on prostate cancer to annual national convention of AST in Orlando. Full house and very engaged audience in light of former Pres Biden recent Dx. We could not do what we love without skilled surgical technologists! Most appreciative

Cognitive effects of abiraterone vs enzalutamide in metastatic castration-resistant #ProstateCancer. Alicia Morgans, MD, MPH Dana-Farber joins Oliver Sartor, MD Mayo Clinic to discuss the results of a study showing minimal measurable changes in objective cognitive testing in both arms

Congrats to you for continuing to build a great team there and kudos to Micheal on his new chapter!

🔬 Racial differences in #mCRPC genomics unveiled! African American tumors show higher MYC & lower inflammatory pathways 🧬🔥 Same outcomes, but distinct biology—diversity in trials is a must! 🌍 ➡️doi.org/10.1038/s41391…